SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer

SELLAS presented preclinical data at the 2026 AACR Pancreatic Cancer conference showing its CDK9 inhibitor SLS009 induced 17.9% apoptosis versus 2.8% for daraxonrasib in a MYC-amplified, daraxonrasib-resistant patient-derived PDAC organoid model. The SLS009/daraxonrasib combination increased apoptosis to 36.5% and necrosis to 30.6%, and SLS009 plus the BET inhibitor ZEN3694 showed synergistic activity with sustained MYC suppression. The data, generated with University of Wisconsin-Madison researchers, support further evaluation of SLS009-based combinations to address resistance to RAS-directed therapy in pancreatic cancer.

•1mo ago

Communities Finalise Life Plans Alongside Renewed Shuar Agreements as Warintza Continues to Advance De-Risking Activities

Solaris renewed its cooperation agreements with Shuar representative organizations FISCH and PSHA, while the Warints and Yawi communities finalized Life Plans that recognize mining as supporting their long-term development objectives, though the plans remain subject to customary community approval. Permitting continues to advance following the EIA's technical approval earlier this year, with water permits, mining concession processes and infrastructure clearances progressing in parallel, and technical drilling on track to be completed by the end of Q4 2026. The company held US$54 million in cash as of June 30, 2026 and expects the third and final US$50 million tranche of the Royal Gold funding package in the fourth quarter, subject to completion of required security filings. Management frames the parallel social, permitting and technical workstreams as progressively de-risking Warintza ahead of the government-led consultation process, though the timing of that consultation remains outside the company's control.

•1mo ago

SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer

SELLAS Life Sciences announced that three abstracts on SLS009 (tambiciclib), its selective CDK9 inhibitor, were accepted for poster presentation at the AACR Conference on Pancreatic Cancer, held September 25-28, 2026 in San Diego. The preclinical studies, run in collaboration with the University of Wisconsin-Madison, test SLS009 across patient-derived KRAS-mutant organoid models of pancreatic ductal adenocarcinoma, including combinations with BET- and KRAS-directed approaches and targeting of MYC-associated vulnerabilities. The posters extend SLS009 beyond its ongoing AML development into solid tumors, but the data are preclinical and carry no near-term regulatory or financial impact.

•1mo ago

The Copper Bottleneck That Rewrites Mining Valuations

Freeport-McMoRan signed a Memorandum of Understanding with the Indonesia government to extend operating rights for the Grasberg minerals district for the life of the resource, pushing the horizon well beyond 2041. Under the agreement, FCX will maintain its 48.76% ownership in PT Freeport Indonesia through 2041 before transferring a 12% share to government interests at no cost, reducing its stake to approximately 37% starting in 2042. The deal commits FCX to increased exploration spending, expanded community investment in Papua, and continued domestic downstreaming of refined copper and sulfuric acid.

•6mo ago